

## Special Issue

# Immunotherapy of Solid Tumors: Progress, Challenges, and Future Roadmap

### Message from the Guest Editors

Immunotherapy can either work by restimulating the patient's immune system to recognize and attack the cancer-associated self-antigens or by passively transferring immune molecules or cells that can directly destroy cancer cells. It is essential to understand the physical, biochemical, and immunological challenges associated with solid malignancies to evaluate immunotherapy-based treatment approaches more critically and conclusively. This Special Issue aims to focus on understanding the ongoing challenges in optimizing immunotherapies for solid malignancies and highlighting endeavors to overcome such roadblocks. Studies in this issue will provide a future roadmap to optimize and evaluate immunotherapies to treat solid malignancies. We look forward to your contributions.

---

### Guest Editors

Dr. Shailendra Gautam

Department of Biochemistry, University of Nebraska Medical Center, Omaha, NE 68198, USA

Dr. Abhijit Aithal

Department of Biochemistry, University of Nebraska Medical Center, Omaha, NE 68198, USA

---

### Deadline for manuscript submissions

closed (31 May 2023)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/123675](https://mdpi.com/si/123675)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).